
José Antonio GirÃ³n-GonzÃ;lez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5976138/publications.pdf

Version: 2024-02-01



José Antonio

#	Article	IF	CITATIONS
1	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology, 2005, 41, 779-789.	3.6	245
2	Progression of Chronic Hepatitis C to Liver Fibrosis and Cirrhosis in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus. Clinical Infectious Diseases, 2003, 36, 491-498.	2.9	230
3	Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. Journal of Rheumatology, 2004, 31, 1560-7.	1.0	164
4	Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. Aids, 2006, 20, 49-57.	1.0	154
5	Dilutional Hyponatremia in Patients With Cirrhosis and Ascites. Archives of Internal Medicine, 2002, 162, 323.	4.3	139
6	Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut, 2006, 55, 409-414.	6.1	111
7	Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver International, 2004, 24, 437-445.	1.9	79
8	Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus–Coinfected Patients With Compensated Cirrhosis. Clinical Infectious Diseases, 2013, 56, 1646-1653.	2.9	77
9	Natural History of Compensated Hepatitis C Virus–Related Cirrhosis in HIVâ€Infected Patients. Clinical Infectious Diseases, 2009, 49, 1274-1282.	2.9	66
10	Pneumonia in HIV-infected patients in the HAART era: Incidence, risk, and impact of the pneumococcal vaccination. Journal of Medical Virology, 2004, 72, 517-524.	2.5	65
11	Soluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock. PLoS ONE, 2017, 12, e0175254.	1.1	60
12	Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clinical and Experimental Immunology, 2009, 158, 219-229.	1.1	54
13	Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. Journal of Antimicrobial Chemotherapy, 2007, 60, 1347-1354.	1.3	50
14	Antiretroviral Therapy Based on Protease Inhibitors as a Protective Factor against Liver Fibrosis Progression in Patients with Chronic Hepatitis C. Antiviral Therapy, 2006, 11, 839-846.	0.6	48
15	Expression of proinflammatory cytokines and their inhibitors during the course of spontaneous bacterial peritonitis. Digestive Diseases and Sciences, 2001, 46, 1668-1676.	1.1	44
16	Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality. Infection and Drug Resistance, 2018, Volume 11, 861-872.	1.1	42
17	Immune Activation Response in Chronic HIV-Infected Patients: Influence of Hepatitis C Virus Coinfection. PLoS ONE, 2015, 10, e0119568.	1.1	41
18	Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients. Antiviral Therapy, 2007, 12, 1225-1236.	0.6	39

JOSé ANTONIO

#	Article	IF	CITATIONS
19	Health-related quality of life in patients with primary Sjögren's syndrome: relationship with serum levels of proinflammatory cytokines. Scandinavian Journal of Rheumatology, 2009, 38, 386-389.	0.6	38
20	Adhesion molecules as a prognostic marker of liver cirrhosis. Scandinavian Journal of Gastroenterology, 2005, 40, 217-224.	0.6	37
21	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology, 2012, 56, 1261-1270.	3.6	37
22	Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. Journal of Viral Hepatitis, 2006, 13, 230-234.	1.0	34
23	Similarities and differences between HIV and SARS-CoV-2. International Journal of Medical Sciences, 2021, 18, 846-851.	1.1	34
24	Usefulness of Sputum Culture for Diagnosis of Bacterial Pneumonia in HIV-Infected Patients. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 362-367.	1.3	33
25	Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 420-427.	0.9	30
26	Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity. World Journal of Gastroenterology, 2016, 22, 1433.	1.4	28
27	Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. Journal of Antimicrobial Chemotherapy, 2006, 58, 140-146.	1.3	25
28	Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliative Medicine, 2008, 22, 965-968.	1.3	25
29	Natural History of Compensated and Decompensated HCV-Related Cirrhosis in HIV-Infected Patients: A Prospective Multicentre Study. Antiviral Therapy, 2007, 12, 899-908.	0.6	25
30	Efficacy of Directly Observed Treatment of HIV Infection: Experience in AIDS Welfare Homes. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 331-335.	1.3	19
31	Incidence of and Factors Associated with Hepatocellular Carcinoma among Hepatitis C Virus and Human Immunodeficiency Virus Coinfected Patients with Decompensated Cirrhosis. AIDS Research and Human Retroviruses, 2006, 22, 1236-1241.	0.5	17
32	T cell receptor excision circles (TRECs), CD4+, CD8+and their CD45RO+and CD45RA+subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Clinical and Experimental Immunology, 2006, 146, 270-277.	1.1	16
33	Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. Journal of Antimicrobial Chemotherapy, 2008, 62, 793-796.	1.3	16
34	Response to Pegylated Interferon Plus Ribavirin Among HIV/Hepatitis C Virus-Coinfected Patients With Compensated Liver Cirrhosis. Clinical Infectious Diseases, 2012, 55, 1719-1726.	2.9	16
35	THIS ARTICLE HAS BEEN RETRACTED: Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation. Liver International, 2011, 31, 850-858.	1.9	15
36	Influence of Genetic Polymorphisms of Tumor Necrosis Factor Alpha and Interleukin 10 Genes on the Risk of Liver Cirrhosis in HIV-HCV Coinfected Patients. PLoS ONE, 2013, 8, e66619.	1.1	15

JOSé ANTONIO

#	Article	IF	CITATIONS
37	Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. Journal of Infection, 2008, 57, 167-169.	1.7	14
38	Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients. PLoS ONE, 2014, 9, e101760.	1.1	14
39	Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antiviral Therapy, 2007, 12, 1225-35.	0.6	14
40	Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. Aids, 2012, 26, 1721-1724.	1.0	13
41	Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects. Journal of NeuroImmune Pharmacology, 2019, 14, 413-422.	2.1	12
42	Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antiviral Therapy, 2006, 11, 839-46.	0.6	12
43	Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study. Antiviral Therapy, 2007, 12, 899-907.	0.6	10
44	Factors related to the chronicity and evolution of hepatitis C infection in patients co-infected by the human immunodeficiency virus. Clinical Microbiology and Infection, 2002, 8, 589-597.	2.8	9
45	Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sjögren's syndrome. Cellular Immunology, 2009, 259, 56-60.	1.4	9
46	Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 487-494.	1.3	9
47	Hepatocyte growth factor and chronic hepatitis C. Revista Espanola De Enfermedades Digestivas, 2010, 102, 365-71.	0.1	8
48	Platelet and endothelial activation are requisites for the development of antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2004, 63, 600-601.	0.5	7
49	Absence of favourable changes in circulating levels of interleukin-16 or β-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection. Clinical Microbiology and Infection, 2005, 11, 57-62.	2.8	6
50	Unsolicited consultation by infectious diseases specialist improves outcomes in patients with bloodstream infection: A prospective cohort study. Journal of Infection, 2018, 77, 503-508.	1.7	6
51	Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon. Clinical Microbiology and Infection, 2004, 10, 1067-1074.	2.8	5
52	Structured Intermittent Interruption of Chronic HIV Infection Treatment with Highly Active Antiretroviral Therapy: Effects on Leptin and TNF-α. AIDS Research and Human Retroviruses, 2006, 22, 307-314.	0.5	4
53	Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. PLoS ONE, 2014, 9, e97262.	1.1	4
54	Fiebre Q aguda: riesgo de desarrollo de endocarditis. Revista Clinica Espanola, 2015, 215, 265-271.	0.2	4

JOSé ANTONIO

#	Article	IF	CITATIONS
55	Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1863-1871.	1.3	4
56	Peripheral Th17 cells expressing β7 intestinal homing receptor in recent and chronic HIV infections. Clinical and Experimental Immunology, 2018, 194, 350-360.	1.1	3
57	Antiretroviral therapy partially improves the abnormalities of dendritic cells and lymphoid and myeloid regulatory populations in recently infected HIV patients. Scientific Reports, 2019, 9, 11654.	1.6	3
58	Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World Journal of Hepatology, 2022, 14, 62-79.	0.8	3
59	What Length of Followâ€Up in Patients with HIV and Hepatitis C Virus Coinfection Is Necessary to Consider the Level of Transaminases to Be "Persistently Normal�. Clinical Infectious Diseases, 2007, 44, 310-311.	2.9	2
60	Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV. Lancet Infectious Diseases, The, 2014, 14, 13-14.	4.6	2
61	Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1879-1884.	1.3	2
62	Assessment of the Palliative Prognostic Index in hospitalized oncologic patients treated by a palliative care team: impact of acute concomitant diseases. Oncotarget, 2018, 9, 18908-18915.	0.8	2
63	Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs. Scientific Reports, 2021, 11, 9824.	1.6	2
64	Neutrophil Expression of T and B Immunomodulatory Molecules in HIV Infection. Frontiers in Immunology, 2021, 12, 670966.	2.2	2
65	Short Communication: Atazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis C. AIDS Research and Human Retroviruses, 2013, 29, 223-225.	0.5	1
66	Determination of glycosylated hemoglobin during hospitalization as an opportunity to assess and optimize glycemic control in our patients: An unresolved matter. EndocrinologÃa Y Nutrición (English) Tj ETQ	q0 0 0.s gBT	/Overlock 10
67	La determinaciÃ ³ n de hemoglobina glucosilada durante la hospitalizaciÃ ³ n como una oportunidad para valorar y optimizar el control glucémico en nuestros pacientes: una asignatura pendiente. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 101-102.	0.8	1
68	Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy. Annals of Hematology, 2019, 98, 1953-1959.	0.8	1
69	HIV antibodies level as a marker of HIV persistence: the role of hepatitis C virus coinfection. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1503-1512.	1.3	1
70	Protocolo diagnóstico y terapéutico de las infecciones pleurales. Medicine, 2018, 12, 3231-3234.	0.0	0